Stoke Therapeutics COO steps down; Huw Nash remains as Chief Business Officer

Stoke Therapeutics, Inc.

Huw Nash, Ph.D., stepped down as COO effective June 18, 2024, by mutual agreement with the company.
Nash continues in his role as Chief Business Officer, retaining business development responsibilities.
No successor Chief Operating Officer was named; the COO position appears eliminated or duties reassigned.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Huw Nash

Chief Operating Officer

STOK · Stoke Therapeutics, Inc.

Effective: 2024-06-18
Filed: June 21, 2024, 7:59 PM ET

On June 18, 2024, Stoke Therapeutics, Inc. (the “Company”) and Huw Nash, Ph.D., the Company’s Chief Operating Officer and Chief Business Officer, announced that they have mutually agreed that Dr. Nash would step down from his position as Chief Operating Officer, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Huw Nash changed role as Chief Operating Officer at Stoke Therapeutics, Inc..

Action: stepped down
Role: Chief Operating Officer

Exact text from the filing

On June 18, 2024, Stoke Therapeutics, Inc. (the “Company”) and Huw Nash, Ph.D., the Company’s Chief Operating Officer and Chief Business Officer, announced that they have mutually agreed that Dr. Nash would step down from his position as Chief Operating Officer, effective immediately.

View on SEC.gov

Stoke Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-165651

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.